Clinical Trial Update: Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating BX-U001, a human umbilical cord-derived mesenchymal stem cell product, for COVID-19 with Acute Respiratory Distress …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• BX-U001 (Human umbilical cord-derived mesenchymal stem cells)

Snippet

Sponsor: Baylx Inc. | Conditions: COVID-19, ARDS | Phase 1, Phase 2 | Status: WITHDRAWN